Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine of once identified to the subjects infected with human immunodeficiency virus (positive VIH), to diagnose latent Tuberculosis, and to treat her with isoniazid for six months, measuring the production of Interferon range pre and posttreatment, to evaluate this way the result of the treatment on the immune response

Detailed Description
-----------------
A descriptive analysis of the data will be made. Means and standard deviations for continuous data frequencies for categorical data will be performed. Wilcoxon test Mann-Whitney U test Chi square will be used for frequency analysis of responders Data Analysis and Statistical Software(STATA).

Official Title
-----------------
Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach

Conditions
-----------------
Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Latent Tuberculosis Infection (LTI)

Intervention / Treatment
-----------------
* Drug: Isoniazid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Accept to participate. Informed consent. Human Immunodeficiency Virus positive test, documented by Western Blot Have not received treatment for latent tuberculosis Have not been diagnosed pulmonary tuberculosis (Tbp) Normal two chest X-rays, Postern-anterior and left lateral. Exclusion Criteria: Active tuberculosis Previous diagnosis of tuberculosis Antecedent of treatment for active o latent tuberculosis Contact with TB patient harboring Multidrug resistance or isoniazid resistant isolates of Mycobacterium tuberculosis. Abnormal liver enzyme levels Hemoglobin below 8 gr/dl Allergy or intolerance to isoniazid Peripheral neuropathy Ingestion of drugs interacting with isoniazid

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: one arm<br>All patients with response to positive purified protein derivative (PPD) test are treated | Drug: Isoniazid<br>* Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Production of interferon gamma, in response to treatment of latent infection |  | Before and after treatment intake | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Latent tuberculosis infection, Human immunodeficiency virus (HIV), Treatment, Isoniazid